Skip to content

AtriCure ATRC Additional Paid-In Capital

Additional Paid-In Capital at other companies

Medtronic logo
MedtronicMDT
$20.93B+0.4%
Pulse Biosciences, Inc. logo
Pulse Biosciences, Inc.PLSE
$548.09M+4.3%
ITG
Integer HoldingsITGR
$755.87M+0.2%
Avanos Medical logo
Avanos MedicalAVNS
$1.7B+0.8%

Other financials

Income statement

See full
Revenue$141.2M+14.3%
Gross profit$109.3M+18.0%
Operating income$526.0K+109%
Net income$108.0K+102%
EPS (diluted)$0.00+100%

Balance sheet

See full
Cash & equivalents$146.2M+46.3%
Total debt$76.2M-3.1%
Total equity$491.7M+8.2%
Total assets$644.0M+8.8%

Cash flow

See full
Operating cash flow-$4.0M+63.8%
CapEx$3.9M+76.6%
Free cash flow-$7.8M+40.6%

Valuation

See full
Market cap$1.43B-9.9%
Enterprise value$1.36B-13.1%
P/S2.6×-0.7×

Profitability

See full
Gross margin75.6%+0.8pp
Operating margin-5.1%-1.3pp
Net margin-5.6%-1.5pp
FCF margin9.7%

Returns & leverage

See full
Return on equity-6.1%-1.3pp
Debt / equity0.2×0.0×
Current ratio4.3×+0.2×

Where this comes from

Reported directly by AtriCure in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: AtriCure’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about AtriCure's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AtriCure's additional paid-in capital?
AtriCure (ATRC) reported additional paid-in capital of $904.51M in Q1 2026.
How has AtriCure's additional paid-in capital changed year-over-year?
AtriCure's additional paid-in capital increased by 4.8% year-over-year, from $863.3M to $904.51M.
What is the long-term trend for AtriCure's additional paid-in capital?
Over 5 years (2020 to 2025), AtriCure's additional paid-in capital has grown at a 4.0% compound annual growth rate (CAGR), from $742.39M to $904.52M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.